EDAP TMS SA (EDAP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
EDAP TMS SA stock (EDAP) is currently trading at $3.91. EDAP TMS SA PS ratio (Price-to-Sales) is 2.12. Analyst consensus price target for EDAP is $6.83. WallStSmart rates EDAP as Sell.
- EDAP PE ratio analysis and historical PE chart
- EDAP PS ratio (Price-to-Sales) history and trend
- EDAP intrinsic value — DCF, Graham Number, EPV models
- EDAP stock price prediction 2025 2026 2027 2028 2029 2030
- EDAP fair value vs current price
- EDAP insider transactions and insider buying
- Is EDAP undervalued or overvalued?
- EDAP TMS SA financial analysis — revenue, earnings, cash flow
- EDAP Piotroski F-Score and Altman Z-Score
- EDAP analyst price target and Smart Rating
EDAP TMS SA
📊 No data available
Try selecting a different time range
Smart Analysis
EDAP TMS SA (EDAP) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and peg ratio. Significant fundamental concerns warrant caution or avoidance.
EDAP TMS SA (EDAP) Key Strengths (0)
Supporting Valuation Data
EDAP TMS SA (EDAP) Areas to Watch (10)
Company is destroying shareholder value
Losing money on operations
Earnings declining -62.20%, profits shrinking
Company is losing money with a negative profit margin
Very expensive relative to growth, significant premium
Very expensive at 5.1x book value
Micro-cap company with very limited liquidity and high volatility
Modest revenue growth at 6.00%
Revenue is fairly priced at 2.12x sales
Moderate institutional interest at 39.22%
Supporting Valuation Data
EDAP TMS SA (EDAP) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 0 register as strengths (avg 0/10) while 10 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, EPS Growth. Some valuation metrics including PEG Ratio (90.47), Price/Sales (2.12), Price/Book (5.06) suggest expensive pricing. Growth concerns include Revenue Growth at 6.00%, EPS Growth at -62.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -59.50%, Operating Margin at -35.50%, Profit Margin at -30.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -59.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 6.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EDAP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EDAP's Price-to-Sales ratio of 2.12x trades at a deep discount to its historical average of 5.46x (2th percentile). The current valuation is 93% below its historical high of 32.04x set in Mar 2006, and 19% above its historical low of 1.78x in Apr 2009. Over the past 12 months, the PS ratio has compressed from ~2.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for EDAP TMS SA (EDAP) · HEALTHCARE › MEDICAL DISTRIBUTION
The Big Picture
EDAP TMS SA is in a turnaround phase, with management focused on restoring profitability. Revenue reached 64M with 6% growth year-over-year. The company is currently unprofitable, posting a -30.8% profit margin.
Key Findings
The company is unprofitable with a -30.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL DISTRIBUTION industry trends, competitive moves, and regulatory changes that could impact EDAP TMS SA.
Bottom Line
EDAP TMS SA is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About EDAP TMS SA(EDAP)
NASDAQ
HEALTHCARE
MEDICAL DISTRIBUTION
USA
EDAP TMS SA, develops, produces, markets, distributes and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States and internationally. The company is headquartered in Lyon, France.